LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $9.75.

A number of brokerages have commented on LFST. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of LifeStance Health Group in a research report on Wednesday, May 27th. The Goldman Sachs Group began coverage on LifeStance Health Group in a report on Friday, June 5th. They issued a “neutral” rating and a $9.00 price objective on the stock. Barclays raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Friday, March 6th. JPMorgan Chase & Co. lifted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Finally, BTIG Research upped their target price on LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, May 8th.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Eric Shuey sold 243,362 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $1,951,763.24. Following the sale, the director directly owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This represents a 21.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Darren M. Black sold 5,899,661 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the completion of the sale, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. The trade was a 20.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 6,868,057 shares of company stock worth $55,048,226. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of LifeStance Health Group by 19.5% in the 3rd quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after purchasing an additional 2,383,728 shares during the period. Tudor Investment Corp ET AL acquired a new stake in LifeStance Health Group during the third quarter valued at $1,040,000. Everhart Financial Group Inc. acquired a new stake in LifeStance Health Group during the fourth quarter valued at $787,000. Integral Health Asset Management LLC purchased a new position in LifeStance Health Group in the third quarter valued at $8,250,000. Finally, First Eagle Investment Management LLC raised its position in shares of LifeStance Health Group by 13.3% in the fourth quarter. First Eagle Investment Management LLC now owns 1,496,466 shares of the company’s stock worth $10,535,000 after acquiring an additional 176,000 shares during the period. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Trading Up 3.9%

Shares of LifeStance Health Group stock opened at $10.27 on Friday. The firm’s 50 day simple moving average is $7.91 and its two-hundred day simple moving average is $7.25. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of 171.08 and a beta of 1.19. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $10.30. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. The business had revenue of $403.48 million during the quarter, compared to the consensus estimate of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The firm’s revenue was up 21.2% compared to the same quarter last year. Analysts predict that LifeStance Health Group will post 0.12 EPS for the current year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.